Dr. Agarwal's Eye Hospital shares fall 7% after ₹2,065 crore block deal
What's the deal? Shares of Dr. Agarwal's Eye HospitalDealroom has a profile for this one. Try Dealroom → fell as much as 7.3% to ₹503 on the BSE on August 12, 2026, after 4.07 crore shares — 12.9% of its equity — changed hands in block deals. The transactions were priced at ₹506.5 per share, valuing the total deal at ₹2,065 crore.
Who's selling? Buyers and sellers were undisclosed, but term-sheet details indicated that Hyperion InvestmentsDealroom has a profile for this one. Try Dealroom →, a TPG private-equity vehicle, and Claymore Investments (Mauritius)Dealroom has a profile for this one. Try Dealroom →, a Temasek HoldingsDealroom has a profile for this one. Try Dealroom → vehicle, were looking to sell an 11% stake worth ₹1,750 crore, with a 2% upsize option worth ₹250 crore. The floor price was set at ₹500 per share, a 7.7% discount to the previous close.
The backdrop: At the end of the June 2026 quarter, Hyperion held 23.09% and Claymore 10.19% of the company. Public shareholders owned 67.89%, while promoters held 32.34%.
The business: The company runs eye-care facilities across India, increasingly focused on premium surgeries. Chief executive officer Adil Agarwal said patients are opting for higher-end procedures such as Femto cataract surgeries, adding “at least a 5%” upside supported by better clinical results.
The numbers: The company reported net profit of ₹55 crore for Q1 FY27, up 44.6% year over year. Revenue from operations rose 26% to ₹614 crore, EBITDA climbed 25.2% to ₹177 crore, and the EBITDA margin stood at 28.5%.
Why now? The company added a record 16 surgical facilities during Q1 FY27 — nearly half of all facilities added across FY26 in a single quarter. It reported 16.3% same-store sales growth, split roughly between higher patient volumes and premiumisation.
The signal: The exit by two major institutional backers marks a partial cash-out from a scaleup that has grown quickly, even as its stock is up 11% since February 2026 and 27% since August 2021. Discounted block deals of this size often pressure a stock short term, but they also signal maturing investor positions in India's expanding private healthcare market.
Read more: MSN
Image credit: ex_magician
